share_log

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

生物技术日报:安进、吉利德去购物,为处于早期乳腺癌的阿斯利康的Lynparza点头,阿尔茨海默氏相关幻觉候选人的决策日
Benzinga Real-time News ·  2022/08/04 21:10
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是过去 24 小时内生物技术领域的主要进展摘要:
Stocks In Focus
焦点股票
AstraZeneca/Merck's Lynparza Scores European Approval In Early Breast Cancer
阿斯利康/默克的Lynparza在早期乳腺癌方面获得欧洲的认可
The European Union has approved AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc's (NYSE:MRK) Lynparza (olaparib) for human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
欧盟已批准阿斯利康有限公司(纳斯达克股票代码:AZN)和默克公司的(NYSE: MRK) Lynparza(olaparib)用于先前接受过新辅助或辅助化疗治疗的人表皮生长因子受体2(HER2)阴性的高危早期乳腺癌。
The approval for Lynparza comes as monotherapy or in combination with endocrine therapy for the adjuvant treatment in the breast cancer setting with germline BRCA1/2 mutations.
Lynparza的批准是单一疗法或与内分泌疗法联合使用,用于具有种系BRCA1/2突变的乳腺癌环境中的辅助治疗。
Syros Bone Marrow Cancer Candidate Poised To Get...
赛罗斯骨髓癌候选...

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发